MOBI · Mobia Medical, Inc. · Executive Compensation
$10.01
-0.24 (-2.34%)
At close · Sep 11
Going-concern doubt
— cleared Aug 11, 2026
The latest filing states the doubt was alleviated.
“In prior reporting periods, the Company concluded that recurring operating losses, negative cash flows from operations, and future expenditures raised substantial doubt about its ability to continue as a going concern. In May 2026, the Company completed its IPO and received net proceeds of approximately $134.0 million. As a result of the additional liquidity provided by the completed IPO, management concluded that the existing cash and cash equivalents are sufficient to fund its operations and meet its obligations for at least one year from the date these condensed unaudited interim financial statements are issued. Accordingly, management concluded that the conditions and events described above do not raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$333.24M
Shares
33.29M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Myriam J. Curet, M.D. | Class II director | Appointed | 2026-08-03 |
| William Harrington | member of the Compensation Committee | Resigned | 2026-07-15 |
| Reza Zadno, Ph.D. | member of the Compensation Committee of the Board | Appointed | 2026-07-15 |
| Reza Zadno, Ph.D. | Class III director | Appointed | 2026-07-15 |
Key facts
CIK
1489993
CUSIP
60705V103
13F (30d)
33 filings
33 filers
Visit website
Investor relations